CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has completed its previously announced call for redemption of $400 million in aggregate principal amount of 3.35% Convertible Senior Subordinated Notes due 2015. Holders of $400 million in aggre...

- Presentations include data from two Phase 2 studies in people with cystic fibrosis who have two copies of the F508del mutation - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that six abstracts from its cystic fibrosis (CF) program w...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex will webcast its presentations at the Bank of America Healthcare conference on Tuesday, May 14, 2013 at 3:40 PM PT and at the Sanford Bernstein Strategic Decisions conference on Wednesday, May 29, 20...

- Interim analysis of the Phase 3b CONCISE study showed SVR12 rates of 87 percent with 12 total weeks of treatment and 97 percent with 24 total weeks of treatment among people who achieved RVR and completed 12 weeks of treatment - AMSTERDAM--(BUSINESS WIRE)-- Vertex Pharmaceuticals ...

-Treatment with combination of VX-661 and ivacaftor for 28 days in two highest dose groups resulted in mean relative increases in lung function (percent predicted FEV1) of 9.0% (p=0.01) and 7.5% (p=0.02) versus placebo - -VX-661 was generally well-tolerated alone and in combination with i...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2013 financial results on Tuesday, April 30, 2013 after the financial markets close. The company will host a conference call at 5:00 p.m. ET. The conference call will be we...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex will webcast its presentation at the 33rd Annual Cowen Health Care Conference on Tuesday, March 5, 2013 at 8:40 a.m. ET and at the Barclays Global Healthcare Conference on Tuesday, March 12, 2013 at ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the Health Service Executive (HSE) in the Republic of Ireland will fund KALYDECO™ (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people ages 6 and older who...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2012 financial results on Tuesday, January 29, 2013 after the financial markets close. The company will host a conference call at 5:00 p.m. ET. The conferenc...